Evogene Regains Nasdaq Minimum Bid Price Compliance

TL;DR

Evogene back above $1 on Nasdaq, dodges delisting.

AI Summary

Evogene Ltd. announced on August 8, 2024, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This notification from The Nasdaq Stock Market LLC signifies that Evogene's ordinary shares have met the minimum bid price requirement.

Why It Matters

Regaining compliance with Nasdaq's minimum bid price rule is crucial for Evogene to maintain its listing on the exchange, avoiding potential delisting and ensuring continued investor confidence.

Risk Assessment

Risk Level: low — The filing is a routine notification of compliance with a listing rule, indicating a positive development with no immediate new risks.

Key Numbers

• $1.00 — Minimum Bid Price (The threshold Evogene needed to meet to regain compliance with Nasdaq listing rules.)

Key Players & Entities

• Evogene Ltd. (company) — The company that received the notification.
• Nasdaq (company) — The stock exchange that issued the notification.
• August 8, 2024 (date) — The date Evogene received the notification.
• $1.00 (dollar_amount) — The minimum bid price required by Nasdaq.

FAQ

Key Financial Figures

• $1.00 — ares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this d

Filing Documents

• zk2431834.htm (6-K) — 11KB
• exhibit_99-1.htm (EX-99.1) — 8KB
• image00001.jpg (GRAPHIC) — 4KB
• 0001178913-24-002540.txt ( ) — 25KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Restoration of Compliance with Nasdaq Listing Rules On August 8, 2024, Evogene Ltd., or Evogene, received formal notification from The Nasdaq Stock Market LLC, or Nasdaq, that Evogene has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires Evogene's ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of Evogene's ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, Evogene has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed. A press release of Evogene announcing its restored compliance with the foregoing Nasdaq Listing Rule is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K. Exhibits Exhibit Number Exhibit Description 99.1 Press release issued by Evogene on August 12, 2024 announcing Evogene's regaining compliance with Nasdaq Minimum Closing Bid Price Rule Incorporation by Reference The contents of this Report of Foreign Private Issuer on Form 6-K (including the contents of Exhibit 99.1 hereto) are incorporated by reference into Evogene's registration statements on Form F-3 (File No. 333-277565) and Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215), as filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 12, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR